← Back to Search

Procedure

Fertility-Sparing Surgery for Endometrial Cancer (FETCH Trial)

N/A

Recruiting

Led By Mark Carey, MD

Research Sponsored by Vancouver Coastal Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adequate duration of progesterone therapy: 6 months

Failure of progestin therapy defined as unsuccessful eradication of hyperplasia or cancer in the uterus, or intolerance to the side effects

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years post-resection

Awards & highlights

FETCH Trial Summary

This trial is testing a new way to remove early stage endometrial cancer without harming fertility.

Who is the study for?

This trial is for women under 40 with early-stage endometrial cancer or atypical hyperplasia who haven't improved with hormone therapy and want to keep their fertility. They should have less than a third of the uterus affected, no severe health issues that could complicate surgery, and a reasonable chance to conceive as assessed by a fertility specialist.Check my eligibility

What is being tested?

The study tests hysteroscopic resection—a surgical procedure using an instrument inserted through the vagina to remove abnormal tissue from the uterus—in patients desiring fertility preservation after unsuccessful hormone treatment for certain uterine conditions.See study design

What are the potential side effects?

While specific side effects are not listed, typical risks of hysteroscopic surgery may include bleeding, infection, injury to the uterus or surrounding organs, and complications related to anesthesia.

FETCH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been on progesterone therapy for at least 6 months.

Select...

Progestin therapy did not work for my uterine condition or I couldn't tolerate its side effects.

Select...

My biopsy shows early-stage endometrial cancer with limited spread.

Select...

My biopsy shows I have atypical endometrial hyperplasia.

Select...

I am under 40 years old.

Select...

I don't have major health issues that would make surgery risky.

Select...

My MRI shows minimal invasion of the muscle layer of my uterus.

Select...

I have taken the required dose of progesterone therapy.

FETCH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years post-resection

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years post-resection

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years post-resection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Conception rate of women attempting pregnancy

Distant disease control rate (long-term failure of hysteroscopic resection)

Local disease control rate (short-term failure of hysteroscopic resection)

+1 more

Secondary outcome measures

Complications/side-effects

FETCH Trial Design

1Treatment groups

Experimental Treatment

Group I: Hysteroscopic uterine resectionExperimental Treatment1 Intervention

This is a prospective single-arm surgical intervention trial.

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of British ColumbiaOTHER

1,416 Previous Clinical Trials

2,467,008 Total Patients Enrolled

2 Trials studying Endometrial Cancer

1,250 Patients Enrolled for Endometrial Cancer

Vancouver Coastal Health Research InstituteLead Sponsor

26 Previous Clinical Trials

5,160 Total Patients Enrolled

Mark Carey, MDPrincipal InvestigatorVancouver Coastal Health

Media Library

Hysteroscopic uterine resection (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04362046 — N/A

Endometrial Cancer Research Study Groups: Hysteroscopic uterine resection

Endometrial Cancer Clinical Trial 2023: Hysteroscopic uterine resection Highlights & Side Effects. Trial Name: NCT04362046 — N/A

Hysteroscopic uterine resection (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04362046 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor include individuals aged 80 and above?

"The age bracket for this medical study requires that participants are between 19 and 39 years old."

Answered by AI

To whom is this trial best suited for enrollment?

"This clinical trial has room for 30 individuals between the ages of 19 and 39 who have been diagnosed with endometrial hyperplasia. Candidates must meet a few prerequisites, such as not having any severe medical conditions that would interfere with surgery, being able to potentially conceive based on an infertility specialist's consultation, and taking either 200mg/day Provera or 160mg/day Megace for 6 months in order to qualify."

Answered by AI

To what extent is this research project being populated?

"Yes, the current information on clinicaltrials.gov confirms that this research is actively recruiting participants. This trial was initially launched on November 15th 2020 and its most recent update took place October 14th 2021; it requires 30 patients from 1 separate site to complete."

Answered by AI

Has the enrollment period for this clinical trial begun?

"As indicated on clinicaltrials.gov, this research is still recruiting patients as of October 14th 2021 since its original posting date in November 15th 2020."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia

Mark Carey 2020. "Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04362046.

All > Congenital Adrenal Hyperplasia